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Abstract: A series of cyclic, disulfide- or dithioether-containing
tetrapeptides based on previously reported potent l- and
d-selective analogs has been explored with the aim of improving
their poor affinity to the j-opioid receptor. Specifically targeted
were modifications of tetrapeptide residues 3 and 4, as they
presumably interact with residues from transmembrane helices 6
and 7 and extracellular loop 3 that differ among the three
receptors. Accordingly, tetrapeptides were synthesized with Phe3
replaced by aliphatic (Gly, Ala, Aib, Cha), basic (Lys, Arg, homo-
Arg), or aromatic sides chains (Trp, Tyr, p-NH2Phe), and with D-Pen
4
replaced by D-Cys4, and binding affinities to stably expressed l-, d-,
and j-receptors were determined. In general, the resulting analogs
failed to exhibit appreciable affinity for the j-receptor, with the
exception of the tetrapeptide Tyr-c[D-Cys-Phe-D-Cys]-NH2, cyclized
via a disulfide bond, which demonstrated high binding affinity
toward all opioid receptors (Kil ¼ 1.26 nM, Kid ¼ 16.1 nM,
Kij ¼ 38.7 nM). Modeling of the j-receptor/ligand complex in the
active state reveals that the receptor-binding pocket for residues 3
and 4 of the tetrapeptide ligands is smaller than that in the
l-receptor and requires, for optimal fit, that the tripeptide cycle of
the ligand assume a higher energy conformation. The magnitude
of this energy penalty depends on the nature of the fourth residue
of the peptide (D-Pen or D-Cys) and correlates well with the
observed j-receptor binding affinity.
Abbreviations: Aib, a-aminoisobutyric acid; Cha,
cyclohexylalanine; RP-HPLC, reverse-phase high-performance
liquid chromatography; CHO, Chinese hamster ovary; TM,
transmembrane a-helix; EL, extracellular loop.
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Introduction
The cloned human l-, d-, and j-opioid receptors (1,2) belong
to the G protein-coupled receptor (GPCR) superfamily of
seven helical transmembrane proteins that mediate the
actions of a majority of hormones and neurotransmitters (3)
and serve as the targets for 50% of marketed drugs (4).
Binding of opioids to their receptors activates Gi/o proteins
and leads to subsequent inhibition of adenylate cyclase,
regulation of ion-channels, and activation of mitogen-
activated protein (MAP) kinases, which in turn produce
complex physiologic responses (5).
An understanding of the mechanism by which ligands
bind to and activate their receptors requires knowledge of
the three-dimensional structure of the receptors with bound
ligand, however, for GPCRs, such precise experimental
information is only available for rhodopsin in its inactive
state (6,7). In the absence of crystallographic structures of
receptor–ligand complexes, two complementary approaches
can be applied to uncover the molecular details of receptor–
ligand interactions. The first approach is directed toward
the determination of the receptor-bound conformation of
the ligands, based on structure–activity profiles and con-
formational studies of the ligands. Small cyclic peptides,
adopting a restricted number of conformations that can be
theoretically predicted or experimentally determined, are
particularly useful for this purpose. The second approach
focuses on the receptor, employing site-directed mutagen-
esis and molecular modeling to deduce receptor structure.
Our previous work combining these two approaches has led
to the development of ligand–receptor interaction models
for two closely related peptide series, analogs of cyclic
tetrapeptides JOM-13 and JOM-6 (Fig. 1), selective for d- and
l-opioid receptors, respectively (8,9).
Our efforts, so far, have been focused on the development
of bioactive conformation of l- and d-opioid ligands, deter-
mination of structural requirements for Tyr1 and Phe3
residues, which are regarded as key residues for recognition
of cyclic tetrapeptides by l- and d-opioid receptors (10–16),
and the study of the role of residues from the binding
pockets of the corresponding receptors (9,17). We have
determined that cyclization of tetrapeptides through an
ethylene bridge, amidation of the C-terminus, and restric-
tion of the Phe3 side chain in the trans (v1 ¼ 180) con-
formation favors l-receptor recognition, while cyclization
through a disulfide bridge, a free carboxylate at the C-ter-
minus, and restriction of the Phe3 side chain in the gauche
(v1 ¼ )60) conformation provides d-selectivity. More-
over, l-receptor mutagenesis and molecular modeling
studies revealed that Tyr1 (v1 ¼ 180) of the l-selective
agonist JOM-6 interacts with Asp147 in transmembrane
helix 3 (TM3), His297 in TM6, and a set of aromatic and
aliphatic side chains from TM3, TM5, and TM6. Also, the C-
terminal amide is close to Glu229 in TM5, while Phe3 (v1 ¼
180) is located in a small cleft between extracellular loop 2
(EL2) and TM7 of the l-receptor, where Trp318 (from TM7),
corresponding to Leu300 in the d-receptor or Tyr312 in the j-
receptor, is largely responsible for selective interaction with
the Phe3 aromatic ring of JOM-6 and its analogs (9).
The current study of analogs of these cyclic tetrapeptides
extends this approach toward the elucidation of the ligand
pharmacophore for the j-opioid receptor. The pharmaco-
logic studies reveal that while the binding profiles of the
l- and d-receptor are relatively similar, the profile of the
j-receptor is unique. As a means of uncovering the
molecular mechanisms of j-specificity we focused our
attention on substitutions of the Phe3 residue of cyclic
tetrapeptides. The Phe residue in the opioid core sequence
Tyr-(Gly)n-Phe (n ¼ 1, 2) is considered a part of an address,
which contributes to ligand selectivity (18). The work pre-
sented here explores analogs of JOM-6 and JOM-13 that
probe the steric, lipophilic, and electronic requirements of
residue 3 as an approach to improve affinity of peptides































Figure 1. Structures of JOM-13 and JOM-6.
Przydzial et al. kappa-Opioid receptor ligand recognition
334 J. Peptide Res. 65, 2005 / 333–342
less conformationally restricted d-Cys residue, designed
to facilitate the adjustment of the conformation of the
tetrapeptide cycle to the j-receptor binding pocket, is also
described. Molecular modeling of the active conformation
of the j-receptor in complex with designed tetrapeptides
helps to explain the improved affinity toward j-receptors of
d-Cys4-containing cyclic tetrapeptides with aromatic
residues in the third position.
Results and Discussion
Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition
by j-receptor
As shown in Table 1, the previously developed l- and
d-selective cyclic tetrapeptides JOM-6 and JOM-13, as well
as the related l- and d-active analog, JOM-5, display only
micromolar binding affinity to j-opioid receptors. In an
attempt to improve j-receptor recognition, we examined
different types of side chain replacement (aliphatic, basic,
and aromatic side chains) for the important third residue
(Phe in JOM-5, JOM-6, and JOM-13) and tested these pep-
tides for binding affinity to l-, d- and j-opioid receptors
stably expressed in mammalian cells (Table 1). As in
JOM-5, JOM-6, and JOM-13, all new analogs were con-
formationally constrained via cyclization through residues
2 and 4, as disulfides or ethylene dithioethers.
In the first series of peptides (1–8) we incorporated ali-
phatic side chains of different size (Gly, Ala, Aib, Cha) as
Phe3 replacements and tested these compounds for opioid
receptor binding affinity (Table 1). Of these analogs, only
Cha3 replacement (compounds 7 and 8), was well-tolerated
by l- and d-receptors (Kil ¼ 1.1 nm, Kid ¼ 11.5 nm, and
Kil ¼ 15.1 nm, Kid ¼ 11.8 nm for 7 and 8, respectively).
However, none of the analogs in this series displayed sig-
nificant binding to the j-receptor.
Next, we explored the effect of basic residue substitu-
tions (Lys, Arg, homo-Arg) for Phe3 in JOM-5 and JOM-6
analogs. Compounds 9–14 were designed to take advantage
of possible electrostatic interaction between basic amine or
guanidinium groups of ligand side chains and numerous
acidic residues in EL2 and EL3 of the j-receptor that might
be involved in peptide binding, judging from j-receptor
mutagenesis and opioid receptor chimera studies (19,20).
We observed that all these substitutions resulted in severe
loss of binding to all opioid receptor types. Only the Arg3
and homo-Arg3 analogs (11–14) displayed significant
(1 lm) binding affinity and this was limited to only l-re-
ceptors. In all other cases, the l-, d- and j-affinities were
very weak (Ki > 10 000 nm).
Compounds 15 and 16, in which d-Pen4 is replaced by
d-Cys4, while Phe3 is retained, were prepared to examine
whether conformational restrictions imposed by the b,
b-dimethyl substituents of d-Pen might be hindering
interactions with the j-receptor. Such substitution could
also affect the distribution between low energy conforma-
tions of the peptide cycle. As seen in Table 1, the incor-
poration of d-Cys4 into compound 15, with cyclization via
an ethylene dithioether bridge, yielded little improvement
of j-binding affinity (Kij ¼ 1320 nm), when compared with
the parent peptide, JOM-6 (Kij ¼ 2650 nm). However, the
presence of d-Cys4 combined with cyclization through a
disulfide bridge dramatically increased j-affinity (70-fold)
relative to its parent peptide, JOM-5. The resulting pep-
tide, 16, displayed moderate-to-high binding affinity to
all three opioid receptors (Kil ¼ 1.26 nm, Kid ¼ 16.1 nm,
Kij ¼ 38.7 nm).
In an attempt to further improve j-affinity, we examined
Phe3 replacements using aromatic side chains with variable
lipophilicity, size, electronic properties and orientation of
aromatic ring. Thus, tetrapeptides 17–24, derivatives of
peptides 15 and 16 with Tyr3-, p-NH
2
Phe3-, or Trp3-substi-
tutions for Phe3, were synthesized and evaluated for
opioid receptor affinity (Table 1). In these analogs, d-Cys4,
which apparently favors j-receptor recognition, was
retained.
As seen in Table 1, the results of Phe3 replacement were
dependent on the mode of peptide cyclization. In general,
cyclization via a dithioether bridge resulted in reduced
j-binding relative to the corresponding disulfide (15 vs. 16;
17 vs. 18; 19 vs. 20). Trp3-substitution is a notable exception
as dithioether-containing 23 has only twofold lower
j-affinity than disulfide containing 24. Less can be said
about p-NH2Phe
3-substitution, as both dithioether- and
disulfide-containing analogs (21 and 22) show no appreci-
able binding to the j-receptor. Compared with the Phe3-
containing lead peptide 16, substitution by bulkier (Trp,
p-NH2Phe), more polar, H-bond capable (Tyr, p-NH2Phe), or
stereochemically altered (d-Phe3) residues all result in
losses of j-binding affinity.
Comparison of binding affinity data for the tested com-
pounds (Table 1) allows several conclusions about struc-
tural requirements for cyclic tetrapeptides binding to
different opioid receptors (Table 2). An aromatic residue in
the third position of the tetrapeptides appears to be essen-
tial for j-receptor recognition and favorable for binding to
l- and d-receptors. The presence of Cha3 is well-tolerated
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Table 1. Opioid receptor-binding affinity for standard peptides (E2078, JOM-6, JOM-5, JOM-13) and new cyclic tetrapeptide analogs with
Phe3- substitution
Peptide sequence Bridgea Analog
Ki (nM) ± SEM
l d j
[N-Met-Tyr1, N-Met-Arg7-D-Leu8]-DynA(1–8)-EtNH2 – E2078 0.1 ± 0.01 1.5 ± 0.06 0.67 ± 0.08
Tyr-c[D-Cys-Phe-D-Pen]-NH2 S-Et-S JOM-6 0.17 ± 0.02 12.0 ± 1.40 2650 ± 401
Tyr-c[D-Cys-Phe-D-Pen]-NH2 S-S JOM-5 5.2 ± 2.6 5.4 ± 0.78 2990 ± 1500
Tyr-c[D-Cys-Phe-D-Pen]-OH S-S JOM-13 197 ± 53 1.3 ± 0.06 >10 000
Tyr-c[D-Cys-Aib-D-Pen]-NH2 S-Et-S 1 286 ± 73 941 ± 52.8 >10 000
Tyr-c[D-Cys-Aib-D-Pen]-NH2 S-S 2 >10 000 3880 ± 148 >10 000
Tyr-c[D-Cys-Ala-D-Pen]-NH2 S-Et-S 3 507 ± 86.7 1360 ± 7.7 >10 000
Tyr-c[D-Cys-Ala-D-Pen]-NH2 S-S 4 >10 000 3410 ± 332 >10 000
Tyr-c[D-Cys-Gly-D-Pen]-NH2 S-Et-S 5 473 ± 29.4 1270 ± 179 >10 000
Tyr-c[D-Cys-Gly-D-Pen]-NH2 S-S 6 1160 ± 158 682 ± 85 >10 000
Tyr-c[D-Cys-Cha-D-Pen]-NH2 S-Et-S 7 1.1 ± 0.15 11.5 ± 2.54 >10 000
Tyr-c[D-Cys-Cha-D-Pen]-NH2 S-S 8 15.1 ± 2.48 11.8 ± 2.05 >10 000
Tyr-c[D-Cys-Lys-D-Pen]-NH2 S-Et-S 9 >10 000 >10 000 >10 000
Tyr-c[D-Cys-Lys-D-Pen]-NH2 S-S 10 >10 000 >10 000 >10 000
Tyr-c[D-Cys-Arg-D-Pen]-NH2 S-Et-S 11 >10 000 594 ± 46.5 >10 000
Tyr-c[D-Cys-Arg-D-Pen]-NH2 S-S 12 >10 000 1440 ± 63.6 >10 000
Tyr-c[D-Cys-hArg-D-Pen]-NH2 S-Et-S 13 >10 000 586 ± 21.3 >10 000
Tyr-c[D-Cys-hArg-D-Pen]-NH2 S-S 14 >10 000 2120 ± 58 >10 000
Tyr-c[D-Cys-Phe-D-Cys]-NH2 S-Et-S 15 0.91 ± 0.25 50.0 ± 22.4 1320 ± 196
Tyr-c[D-Cys-Phe-D-Cys]-NH2 S-S 16 1.26 ± 0.25 16.1 ± 3.77 38.7 ± 1.84
Tyr-c[D-Cys-D-Phe-D-Cys]-NH2 S-Et S 17 1200 ± 441 2640 ± 242 >10 000
Tyr-c[D-Cys-D-Phe-D-Cys]-NH2 S-S 18 51.9 ± 15.3 179 ± 24 3010 ± 283
Tyr-c[D-Cys-Tyr-D-Cys]-NH2 S-Et-S 19 ND ND >10 000
Tyr-c[D-Cys-Tyr-D-Cys]-NH2 S-S 20 330 ± 117 21 ± 1.8 627 ± 42
Tyr-c[D-Cys-p-NH2Phe-D-Cys]-NH2 S-Et-S 21 2.6 ± 0.5 655 ± 44 >10 000
Tyr-c[D-Cys-p-NH2Phe-D-Cys]-NH2 S-S 22 160 ± 18 609 ± 61 >10 000
Tyr-c[D-Cys-Trp-D-Cys]-NH2 S-Et-S 23 34.9 ± 4.0 0.51 ± 0.14 370 ± 75
Tyr-c[D-Cys-Trp-D-Cys]-NH2 S-S 24 20.6 ± 12.4 1.3 ± 0.3 174 ± 53
a. Bridge between second and fourth amino acids. S-Et-S denotes S-CH2-CH2-S.
ND, not determined.
Table 2. The structural requirement for cyclic tetrapeptides with high affinity to l-, d- and j-receptors
Receptor (ligand) Ki ± SEM (nM) Residue 3 Residue 4 C-terminus Bridge
Side chain rotamer (v1, )
Residue 3a Residue 2b Residue 4b
l (JOM-6) 0.17 ± 0.02 Phe3 D-Pen4 CONH2 S-Et-S 180 180 )60
d (JOM-13) 1.3 ± 0.06 Phe3 D-Pen4 COO) S-S )60 180 )60
j (16) 38.7 ± 1.84 Phe3 D-Cys4 CONH2 S-S 180 )60 60
a. The orientations for Phe3 side chain in cyclic tetrapeptide favorable for l-, d-, and j-binding have been previously reported (8,15).
b. The conformation of bridge, corresponding to the low energy conformations of JOM-13 (14), and JOM-6 (9), and to the alternate confor-
mation of disulfide for 16.
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in l- and d-receptors, but is unfavorable for binding to
j-receptors. Cyclization via an ethylene dithioether
bridge favors l-receptor binding, while the smaller
disulfide-containing cycle is preferred for peptide recogni-
tion by d- and j-receptors. The presence of a C-terminal
amide favors ligand binding to l- and j-receptors, while a
free C-terminal carboxylate favors binding to the d-receptor
and enhances d-receptor selectivity by diminishing binding
to l- and j-receptors. The presence of d-Cys4 in place of
d-Pen4 in the tripeptide cycle dramatically increases
j-binding affinity of the tetrapeptides, while retaining high
l- and d-affinity. To reveal the molecular mechanisms
underlying differences in structural requirements for
recognition of tetrapeptides from this series by the three
opioid receptors we modeled the active j-receptor in com-
plex with cyclic tetrapeptides and compared the result with
our previously developed model of the active l-receptor in
complex with JOM-6 (9).
Homology model of active j-opioid receptor with bound cyclic
tetrapeptide
Homology modeling of the j-receptor in complex with
cyclic tetrapeptides (JOM-6 and peptide 16) was undergone
using distance geometry methods, as described in Experi-
mental Procedures. The sequence alignment of opioid
receptors and rhodopsin was previously verified using
intrinsic and engineered Zn2+-binding centers and many
other experimental data (17). The alignment assumes dis-
appearance of an a-aneurism in TM2 existing in rhodopsin
and conservation of the b-hairpin observed in EL2 of rho-
dopsin. This b-hairpin, connected by a conserved disulfide
bridge to TM3, is a typical feature of many rhodopsin-like
GPCRs (6,7,17,21–24) and can be expected to occur in
opioid receptors based upon their sequence similarity to
rhodopsin in this region (17).
The j-receptor model calculated here is a significant
improvement over earlier models that were calculated with
hydrogen bonding constraints (21), or obtained from the
bacteriorhodopsin template and low-resolution electron
microscopic (EM) maps (25–32). Moreover, it also differs
from automated modeled j-receptors deposited in modbase
(33) in several important details, such as target-template
sequence alignment in TM2, TM7, and EL2. The present
j-receptor model is close to the crystal structure of rho-
dopsin (7) with RMSD of 2.21 Å for 212 Ca-atoms (TM
domain) and 1.43 Å for 174 Ca-atoms (all a-helices, except
TM6). It also reproduces TM6 movement, shift of EL2 and
other characteristics of our structural template, the acti-
vated l-receptor (9), which was recently calculated from
the crystal structure of rhodopsin and a set of activating
distance constraints, derived from experimental studies of
different GPCRs in the active conformation (9). The tetra-
peptide ligands (JOM-6 and peptide 16) were included in
calculations of j-receptors in a manner similar to the cal-
culation of the l-receptor–JOM-6 complex (9).
The calculated model of the active j-receptor with bound
peptide 16 is nearly identical to the l-receptor model with
JOM-6 in the TM domain (RMSD 0.76 Å for 212 Ca-atoms).
In the area of the Tyr1-binding site, the aromatic side chain
of Tyr1 is surrounded by Tyr139, Met142, Phe143, and Phe231.
Tyr1 has aromatic interactions with the indole ring of
Trp287, its N+ group forms an ionic pair with Asp138, and
its OgH group forms H-bonds with His291 and the back-
bone of Ala234 (Fig. 2). These interactions of the tyramine
portion of the ligands are conserved for all opioid receptors
(17,21).
However, another area of the binding pocket, responsible
for interactions with the third and fourth residues of the
tetrapeptides, differs among the three opioid receptors. The
key residues that appear to be responsible for selective
interaction of peptide ligands with these receptors are
located in TM6 (Lys303 in l-, Trp294 in d- and Glu297 in
j-receptor), TM7 (Trp318 in l-, Leu300 in d- and Tyr312 in
j-receptor), and EL2 (17). In the l-receptor, the Phe3 side
chain of JOM-6 (v1 ¼ 180) occupies a cleft between EL2-
and TM7, and has effective aromatic interactions
with Trp318 from TM7 and Phe221 from EL2 (Fig. 3A). This
cleft provides enough space for Phe3. Further, the peptide
d-Pen4 residue interacts with Lys303 from TM6 and the
C-terminal CONH2 is pointed between TM5 (Glu
229) and
Figure 2. Stereoview of peptide 16 (Tyr-c[d-Cys-Phe-d-Cys]NH2, S-S
bridge) inside the j-opioid receptor binding pocket. Ligand is repre-
sented in purple licorice surrounded by dot surface. Receptor residues
participating in the interaction with Tyr1 and Phe3 are shown colored
by residue type: white for aliphatic, green for aromatic, yellow for un-
charged polar, red for acidic, blue for basic, purple for sulfur-containing
residues.
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EL2 (Phe221). At the d-receptor the peptide ligand’s Phe3
side chain (v1 ¼ )60) is also located in a cleft between
EL2 and TM7, interacting with Leu300 from TM7 and
Phe202 from EL2, while d-Pen4 contacts with Trp284 from
TM6 and the C-terminal -COO- is located between EL2 and
TM5.
In contrast, in the j-opioid receptor, the cleft between
TM7 and EL2 is narrowed because of two residues inserted
into the b-turn of the b-hairpin in EL2, Asp204, and Val205.
The corresponding residues are present in bovine rhodopsin
but are missing in l- and d-opioid receptors. For cyclic
tetrapeptide ligands the side chain of Phe3, but not the
larger Trp3 side chain, can squeeze into the tight cleft
between TM7 and EL2, interacting with Tyr312 (substituted
for Trp318 of the l-receptor), Phe214 and polar side chains
of Asp204 and Glu209 from EL2 (Fig. 3B). The Trp fi Tyr
replacement in TM7 of the j-receptor and the smaller-size
of the binding cleft may contribute to the 30-fold decreased
binding affinity of peptide 16 for the j-receptor, relative to
the l-receptor.
The most intriguing result in Table 1 is the dramatic
improvement of j-recognition by peptide 16 (with d-Cys4
and S-S bridge) relative to JOM-5 (with d-Pen4 and S-S
bridge), to peptide 15 (with d-Cys4 and dithioether bridge),
or to JOM-6 (with d-Pen4 and dithioether bridge). The
comparison of modeled complexes of l-receptor with bound
JOM-6 and of j-receptor with bound peptide 16 helps
explain these results. In the j-receptor, the space available
for interaction with the ligand’s fourth residue and disul-
fide/dithioether bridge is reduced relative to the l-binding
pocket because of the insertion of one residue in EL2 near
TM5. As a result, the narrowed binding pocket of the
j-receptor can more easily accommodate peptides with a
smaller-size cycle. This explains the better j-binding
affinity of peptides with a disulfide bridge and d-Cys4 rel-
ative to peptides with dithioether bridge and d-Pen4.
Moreover, in the tight j-receptor pocket, peptide 16, with a
tripeptide cycle conformation analogous to JOM-6 at the
l-receptor (9), displays hindrances between its C-terminal
carboxamide and Phe214 in EL2. The l-receptor bound
conformation of JOM-6 represents the lowest energy con-
formation of the peptide cycle with v1 ¼ 180 for d-Cys2
and v1 ¼ )60 for d-Pen4 (9). A similar conformation of
the disulfide bridge was deduced for the d-receptor-bound
conformation of JOM-13 and JOM-5 (14). However, only a
higher energy, alternative conformation of the disulfide
bridge in peptide 16 (v1 ¼ )60 for d-Cys2 and v1 ¼ 60
for d-Pen4), which reorients the carboxamide toward TM6,
can fit the smaller j-binding pocket. For the d-Pen4-con-
taining JOM-5, the energy gap between the proposed
d-receptor bound conformation and the alternative confor-
mation is >3.5 kcal/mol, but this gap decreases to 2 kcal/
mol in d-Cys4-containing peptide 16. As a result, the energy
penalty for binding in an unfavorable cycle conformation is
much smaller for d-Cys4-containing peptides and explains
their reasonably high j-affinity. At the same time, this
2 kcal/mol energy penalty correlates well with the
30-fold higher affinity of 16 for the l- vs. j-receptor, as for
binding of 16 to the l-receptor the lowest energy confor-
mation is allowed.
Figure 3. JOM-6 in the l-opioid receptor binding pocket (A, thick lines) and peptide 16 in the j-opioid receptor binding pocket (B, thick lines). In each
figure, ligand and receptor residues from the other figure are depicted in thin lines for comparison. Ligands are colored purple, receptor residues
are colored by residue type, as in Fig. 2.
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Conclusions
Our receptor modeling exposes differences between the
ligand-binding pockets of l-, d-, and j-opioid receptors in the
area of the likely interaction site with the third and the fourth
residues of the ligands. We have recently shown that, in l-
and d-receptors, EL3 and the extracellular parts of TM6, TM7
are important for binding of cyclic tetrapeptides (8,9,17). In
particular, Phe3 of the tetrapeptide interacts with a cleft
between EL2 and TM7, where Trp318 from TM7ofl-receptors
or the corresponding Leu300 of d-receptors is implicated in
selective recognition of Phe3 in trans- or gauche-orienta-
tions, respectively. Moreover, Lys303 from TM6 of the l-
receptor or the corresponding Trp284 of the d-receptor forms
additional specific interactions with d-Pen4 of tetrapeptides.
Our current j-receptor model demonstrates that, in the
j-receptor, the binding pocket between EL2, TM6, and TM7
is narrowed due to insertion of two residues in the b-turn of
EL2 and one residue in EL2 near TM5. The tight cleft
between TM7 and EL2 can only accept the small aromatic
side chain of Phe3 while the larger Tyr3, p-NH2Phe
3, and
Trp3 side chains are not accommodated. Accordingly, the
Phe3, d-Cys4-containing peptide, 16, displayed the best
j-binding affinity of the series (Ki ¼ 38.7 nm). In the
j-receptor, Phe3 of 16 effectively interacts with Tyr312 from
TM7, Phe214, and Asp204 from EL2. The lower j-binding
affinity of this peptide relative to its l-receptor binding is
consistent with the steric constraint imposed by EL2 of the
j-receptor, which requires 16 to assume a high-energy con-
formation of its peptide cycle in the tight j-binding pocket.
As noted above, the tetrapeptide residue 3-binding site of
the j-receptor includes the polar, acidic side chains of
Asp204 from EL2 and Glu297 from TM6. Attempts to exploit
these acidic residues for improved binding by incorporating
Lys3, Arg3, or hArg3 in tetrapeptides were unsuccessful
presumably due to the water-exposed nature of this binding
region, such that any energy gain from electrostatic inter-
actions between the basic peptide side chain and the acidic
receptor residues is offset by the energy cost of dehydration
of these polar residues.
Experimental Procedures
Materials
All Fmoc-protected amino acids were obtained from
Advanced ChemTech (Louisville, KY, USA) or Chem-
Impex International (Wood Dale, IL, USA). All other
reagents were from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise indicated.
Solid-phase peptide synthesis
All peptides were synthesized by solid-phase methods on an
ABI Model 431A solid-phase peptide synthesizer (Applied
Biosystems, Foster City, CA, USA). Rink resin (Advanced
ChemTech, Louisville, KY, USA) was used as the solid
support for C-terminal carboxamide peptides. Peptide elon-
gation on the peptide-resin involved treating resin with
piperidine (Aldrich, Milwaukee, WI, USA) to cleave the
Fmoc-protecting group, followed by coupling of the next
amino acid with o-benzotriazol-1-yl-N,N,N¢,N¢-tetramethyl
uronium hexafluorophosphate (HBTU) and 1-hydrox-
ybenzotriazole (HOBt) (Applied Biosystems). Trifluoroacetic
acid/H
2
O/thioanisole/ethylenedithiol (9 : 0.5 : 0.25 : 0.25,
v/v/v/v) was used to cleave the linear peptide from the
resin and simultaneously remove the side chain-protecting
groups. The peptide solution was filtered from the resin
and then subjected to preparative reverse-phase high-per-
formance liquid chromatography (RP-HPLC) to afford the
linear disulfhydryl-containing peptide. Final product con-
firmation was obtained by ESI-LC-MS (ThermoFinnigan,
San Jose, CA, USA).
General method for disulfide cyclization of peptides
To obtain disulfide cyclized peptide, linear disulfhydryl-
containing peptide was dissolved in a 1% (v/v) acetic acid
(HOAc) in H2O solution (saturated with N2) at 5 C (1 mg
linear peptide/mL of aqueous HOAc solution). The pH of the
peptide solution was raised to 8.5 using NH4OH, followed
by the addition of 4 LEq of K3Fe(CN)6. The reaction mixture
was stirred for 1 min, then quenched by adjusting the pH to
3.5 with HOAc. The mixture was then subjected to prepar-
ative RP-HPLC to afford the disulfide-cyclized peptide.
General method for dithioether cyclization of peptides
To form dithioether-containing cyclic peptides, linear
disulfhydryl peptide was added to dimethylformamide and
maintained at 5 C under a N2 atmosphere (0.1 mg linear
peptide/mL dimethylformamide). About 10 mEq of potassium
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tert-butoxide were added to the peptide solution, followed by
the addition of 10 mEq of Br-(CH2)n-Br (n ¼ 1, 2, or 3). The
reaction was quenched with 5 mL HOAc after 2 h and the
solvent was removed in vacuo. The residue was dissolved in
water, filtered, and then subjected to preparative RP-HPLC to
afford the alkyl dithioether-cyclized peptide.
All final product peptides were >95% pure as assessed by
RP-HPLC on a Vydac 218TP C-18 column (The Nest Group,
Southboro, MA, USA) using the solvent system 0.1% tri-
fluoroacetic acid (TFA) in water/0.1% TFA in acetonitrile
by a gradient of 0–70% organic component in 70 min,
monitored at 230 nm, and all peptides displayed the
appropriate molecular weights as determined by mass
spectrometry. Table 3 summarizes the analytical data for
all 24 new peptides.
Radioligand-binding assays
Opioid ligand-binding assays were based on the displace-
ment by the test compounds of 3H-diprenorphine from
opioid receptors (rat l and d, human j) cloned and stably
expressed in rat glioma C6 cells (l and d) or Chinese ham-
ster ovary (j) cells as previously described (34,35). The assay
mixture, containing membrane suspension in 50 mm Tris
buffer (pH 7.4), radiolabeled ligand, and test compound, was
incubated at 25 C in triplicate for 1 h to allow binding to
reach equilibrium. Subsequently, the samples were filtered
rapidly, and the radioactivity retained was determined by
liquid scintillation counting. Inhibition of radiolabeled
ligand binding by the test compounds was determined from
maximal specific binding, measured with an appropriate
excess of unlabeled naloxone (10 lm). IC
50
-values were
determined by nonlinear regression analysis to fit a logistic
equation to the competition data and converted to Ki-values
using graphpad prism software. The results presented are
the mean ± SEM from at least three separate assays.
Distance geometry calculations of j-receptor–tetrapeptide
complexes
The comparative modeling of human j-receptor (residues
55–348, accession code P41145) was performed using the
distance geometry program diana (36), quanta (Accelrys,
San Diego, CA, USA), and our supplementary software, as
described previously (9,17,21,37). The l-opioid receptor
model (active state) in complex with JOM-6 (9) was applied
as a structural template. During distance geometry calcu-
lations, the spatial positions of all TM helices were re-
strained using the following upper distance constraints: (i)
the corresponding Cb…Cb distances from the template,
with deviations of 1 Å, (ii) a set of H-bonds specific for j-
opioid receptor (O…O, N…O distances of 2.9 Å), and (iii) a
conserved disulfide bond between Cys131 and Cys210
(Sc…Sc, Cb…Cb, Cb…Sc distances of 2.04, 4.20, 3.05 Å,
respectively). This allowed small spatial adjustments of all
a-helices during the calculations. The dihedral angles of
receptor residues were generally taken as in the template,
with allowed deviations of 30. The side chain rotamers of
some residues nonidentical in l- and j-receptors were
changed to remove steric clashes and to maximize the
number of interhelical H-bonds. The standard target func-
tion weights and minimization protocol were applied (36).
The pairwise RMSD between the 10 best calculated models
of the j-receptor was <0.6 Å (for 294 Ca-atoms).











1 525.2 526.2 21.4
2 497.2 498.0 20.5
3 511.2 512.2 19.8
4 483.2 484.0 19.0
5 497.2 498.1 19.6
6 469.2 470.1 18.9
7 593.3 594.2 28.5
8 565.3 566.1 23.5
9 568.3 569.2 19.8
10 540.2 541.2 18.8
11 596.3 597.4 19.8
12 568.2 569.6 19.1
13 610.3 611.4 19.9
14 582.3 583.3 19.0
15 559.2 560.2 20.9
16 531.2 532.1 17.6
17 559.2 560.2 20.6
18 531.2 532.1 20.3
19 547.2 548.1 15.3
20 575.2 576.1 18.1
21 602.3 603.2 19.8
22 574.2 575.2 19.4
23 598.2 599.1 22.9
24 570.2 571.1 19.7
a. Molecular weight determined by ESI-LC-MS.
b. Retention time assessed by analytical high-performance
liquid chromatography (HPLC): 0–70% acetonitrile, w/0.1%
trifluoroacetic acid (TFA) in 70 min, 230 nm, samples in H2O,
w/0.1% TFA (elution column heated at 35 C).
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Cyclic peptides were included in the distance geometry
calculations as described previously (9). The lowest
energy conformers of peptide 16 with relative energies
DE < 5 kcal/mol and four alternative conformations of dis-
ulfide bridge were obtained by molecular mechanics com-
putations using the quanta2000.2/charms force field (14).
These conformers were tested during modeling of j-recep-
tor–peptide complexes. Moreover, we concluded that the
aromatic side chain of residue 3 of the peptide ligand would
have a trans-rotamer when bound to the j-receptor, similar
to the orientation of Phe3 bound to the l, but not the
d-receptor (8). This conclusion was based on our previous
data, which indicated that the incorporation of DE-Phe3 in
JOM-5, which fixes the aromatic side chain in a trans-
orientation, improves j-affinity (15,16).
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